Cargando…

Reductions in Heart Failure Hospitalizations During the COVID-19 Pandemic

Detalles Bibliográficos
Autores principales:	HALL, MICHAEL E., VADUGANATHAN, MUTHIAH, KHAN, MUHAMMAD SHAHZEB, PAPADIMITRIOU, LAMPROS, LONG, ROBERT C., HERNANDEZ, GABRIEL A., MOORE, CHARLES K., LENNEP, BRANDON W., MCMULLAN, MICHAEL R., BUTLER, JAVED
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7219367/ https://www.ncbi.nlm.nih.gov/pubmed/32405232 http://dx.doi.org/10.1016/j.cardfail.2020.05.005

Ejemplares similares

What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

The Limitations of Symptom-based Heart Failure Management
por: Papadimitriou, Lampros, et al.
Publicado: (2019)

Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis
por: Butler, Javed, et al.
Publicado: (2020)

Targeting Mitochondrial Function in Heart Failure: Makes Sense But Will it Work?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2019)

Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure
por: Usman, Muhammad Shariq, et al.
Publicado: (2022)

Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Sodium–Glucose Cotransporter-2 Inhibitors and Heart Failure Prevention in Type 2 Diabetes
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2019)

Recognizing the Significance of Outpatient Worsening Heart Failure
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Shielding the Heart: Preload Reduction Therapies in Heart Failure
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2023)

Trends and characteristics of hospitalizations for heart failure in the United States from 2004 to 2018
por: Salah, Husam M., et al.
Publicado: (2022)

A rationale for dedicated trials of combination therapy in heart failure
por: Blumer, Vanessa, et al.
Publicado: (2022)

Frailty and heart failure: State‐of‐the‐art review
por: Talha, Khawaja M., et al.
Publicado: (2023)

Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019
por: Leiva, Orly, et al.
Publicado: (2020)

Evolving therapeutic strategies for patients hospitalized with new or worsening heart failure across the spectrum of left ventricular ejection fraction
por: Ostrominski, John W., et al.
Publicado: (2022)

Torrential Mitral Regurgitation After Transcatheter Edge-to-Edge Mitral Valve Repair
por: Blossom, Jonathan, et al.
Publicado: (2021)

Renin–angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta‐analysis
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2017)

The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction
por: Greene, Stephen J., et al.
Publicado: (2013)

High‐Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network
por: Fudim, Marat, et al.
Publicado: (2018)

Determinants of exercise intolerance symptoms considered non-specific for heart failure in patients with stage A and B: role of the left atrium in the transition phase to overt heart failure
por: Maffeis, Caterina, et al.
Publicado: (2021)

Prescription Filling Patterns of Evidence-Based Medical Therapies for Heart Failure During the COVID-19 Pandemic in the United States
por: Vaduganathan, Muthiah, et al.
Publicado: (2021)

Comparison of Machine Learning Methods With Traditional Models for Use of Administrative Claims With Electronic Medical Records to Predict Heart Failure Outcomes
por: Desai, Rishi J., et al.
Publicado: (2020)

Discontinuation and non‐publication of heart failure randomized controlled trials: a call to publish all trial results
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2020)

Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post‐hoc analysis of the ATHENA trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2022)

Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials
por: Fiuzat, Mona, et al.
Publicado: (2022)

Primary Prevention of Heart Failure
por: Butler, Javed
Publicado: (2012)

Impact of Diabetes on Outcomes in Patients Hospitalized With Acute Myocardial Infarction: Insights From the Atherosclerosis Risk in Communities Study Community Surveillance
por: Jain, Vardhmaan, et al.
Publicado: (2023)

Impact of COVID-19 on Heart Failure Clinical Trials: Insights From the Heart Failure Collaboratory
por: Bhatt, Ankeet S., et al.
Publicado: (2023)

Acute Cardiovascular Complications of COVID-19: The High Risk of Underlying Heart Disease
por: Mensah, George A., et al.
Publicado: (2023)

Pressures do not equal volumes: implications for heart failure management in patients with CardioMEMS
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2022)

Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19
por: Bhatt, Ankeet S., et al.
Publicado: (2021)

Regulation of Cardiovascular Therapies During the COVID-19 Public Health Emergency
por: Vaduganathan, Muthiah, et al.
Publicado: (2020)

Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2022)

Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
por: Tomasoni, Daniela, et al.
Publicado: (2022)

Extracorporeal Life Support for Pediatric Heart Failure
por: Burke, Christopher R., et al.
Publicado: (2016)

Heart Failure
por: Giamouzis, Gregory, et al.
Publicado: (2011)

Effect of Carillon Mitral Contour System on patient‐reported outcomes in functional mitral regurgitation: an individual participant data meta‐analysis
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2021)

Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency
por: Butler, Javed, et al.
Publicado: (2022)

The Intersection of Type 2 Myocardial Infarction and Heart Failure
por: McCarthy, Cian P., et al.
Publicado: (2021)

Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR‐Reduced
por: Anker, Stefan D., et al.
Publicado: (2022)

Response to Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care 2019;42:2298–2306
por: Segar, Matthew W., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jc23smbgu45ia6cavbvfojj84i